CNR1 and obesity due to melanocortin 4 receptor deficiency: By contrast, a CB1R antagonist/inverse agonist, rimonabant (Acomplia®), was approved in 2006 to treat obesity, and metabolic syndrome (Carai et al., 2006) and generated extremely high expectations.